TriArm Therapeutics Secures $60 Million Series A Financing to Accelerate Next-Generation Cell Therapy Development

TriArm Therapeutics Limited (hereinafter referred to as "TriArm") today announced the completion of its Series A financing, comprising three tranches in total. This brings TriArm's total Series A funding to $60 million.The Series A funding was backed by Panacea Venture, VI Venture, HT Capital, Efung Capital, LO Co-Investment Fund, Jinpu Health Fund, Ruifu Healthcare Investment Fund, and other international investment firms.Strongly support.

TriArm Therapeutics Limited is a next-generation cell therapy company initiated by Panacea Venture and co-founded by CEO Dr. Jay Zhang and Chief Scientific Officer Dr. Jim Lu. The company maintains multiple innovative pipelines, with one candidate already initiating clinical trials in both Taipei and Shanghai, and another conducting clinical research in Germany. Two additional candidates are currently undergoing clinical study planning. The company is concurrently advancing its product portfolio across TriArm Therapeutics (Shanghai), Chuang'en Biomed (Taipei), and TriArm Germany.

Dr. Jay Zhang, Chief Executive Officer of TriArmstated: “We are deeply grateful for the support from our investors and all sectors. This not only affirms TriArm’s efforts but also strongly validates our vision. We thank our team for overcoming various challenges and efficiently advancing the project. Within a remarkably short period, we have secured IND approval in Taiwan, initiated clinical trials in Germany, and smoothly advanced clinical development in China. This round of financing will significantly accelerate the company’s expansion of its highly distinctive technology platform and the development of practical, innovative cell therapy products.”

TriArm Chief Scientific Officer Dr. Jinhua Lu (Jim Lu)stated: "We will further establish and refine our proprietary immune cell molecular design and cell expansion platform technologies, enrich our pipeline in hematologic malignancies and solid tumors, and vigorously advance the clinical development of existing projects. We welcome diverse forms of collaboration to expand the breadth and depth of our translational research and technological pathways in oncology, autoimmune diseases, and infectious diseases, and to develop more innovative projects."

TriArm Chief Operating Officer and General Manager, Taipei Office, Liren Chen (Mike Chen)stated: “The new financing will significantly accelerate TriArm’s progress in clinical research, manufacturing scale-up, and ultimate commercialization, and expedite industry collaborations to benefit patients.”

Founded in early 2019, it is a high-tech multinational corporation initiated by Panacea Venture and co-founded by several senior executives and R&D professionals in the biomedical technology sector. The company currently operates R&D entities in Shanghai, Taipei, and Regensburg, Germany, focusing on the clinical translation of innovative cellular immunotherapy products and dedicated to delivering next-generation cell therapies to cancer patients. TriArm Therapeutics, its Shanghai-based subsidiary, has established a 1,500-square-meter GMP-compliant cell therapy R&D facility in Zhangjiang, Shanghai. Furthermore, the company has launched collaborative R&D initiatives with innovative cellular research teams and medical institutions across the Asia-Pacific region, Europe, and the Americas. TriArm has officially initiated the industrialization of its cell therapies in mainland China, aiming to establish an internationally competitive industrial hub that integrates R&D, manufacturing, standardized quality control, and clinical services. Its Taipei subsidiary, Chuang'en Biomed, operates a comprehensive clinical-grade manufacturing team and is actively advancing various clinical development and industrialization efforts. Meanwhile, TriArm’s German team is dedicated to the research and development of innovative therapeutic pipelines.

Panacea Venture, also known as the Ruifu Healthcare Fund, primarily invests in and incubates early- and growth-stage companies globally in the life sciences and healthcare sectors that are R&D-driven, innovative, and characterized by high technological barriers. Through breakthrough technologies and inventions, it aims to address unmet medical needs and improve patients' quality of life. The investment team comprises the former life sciences investment professionals from the globally renowned venture capital firm KPCB China, alongside senior industry experts.

As a boutique investment firm, Virtus Inspire Venture is dedicated to helping entrepreneurs realize their visions and collaboratively build a better world. It provides funding from the seed and startup stages through to growth. Concurrently, it delivers professional services to portfolio companies in branding, marketing, channel development, cross-border expansion, human resources, and finance. Its investment focus spans life sciences, medical technology, and TMT, with a geographic reach across the United States, Israel, and China. Additionally, it serves as a strategic bridge to facilitate the cross-border expansion of domestic and overseas enterprises.

As a professional investment institution, HT Capital provides investment services spanning both the primary and secondary markets. It has invested in over 80 private funds globally, covering most leading angel, VC, and PE institutions as well as securities funds; it has also made direct investments in more than 290 projects, with a particular focus on the healthcare, technology, and internet industries.

Shanghai Jinpu Medical & Health Equity Investment Fund Management Co., Ltd. (hereinafter referred to as "Jinpu Health Fund") is a specialized fund management company under Jinpu Investment, focusing on equity investments in the medical and healthcare industry. Its investment areas encompass biotechnology and pharmaceuticals, medical devices, mobile health, and healthcare services. Jinpu Health Fund conducts in-depth exploration along the upstream and downstream value chains of the medical and healthcare sector. Acting as a value discoverer, it engages early in high-potential projects and provides full-lifecycle tracking. By facilitating resource integration and enhancing the value of its portfolio companies, it ultimately positions itself as a value creator.

Efung Capital, also known as Yifeng Capital, is a specialized investment firm focused on the global biopharmaceutical sector. Aiming to leverage capital to drive the commercialization of biotechnological innovations, it manages both RMB and USD funds and has successively invested in high-quality domestic and international projects such as Chipscreen Biosciences, Ascentage Pharma, and Centrexion Therapeutics.

Lombard Odier Co-Investment, also known as Lombard Odier Asset Management, is the asset management business of Lombard Odier, specializing in serving institutional investors, third-party distributors, and financial intermediaries. Through proprietary portfolio management systems, information technology, and operational infrastructure, coupled with global custody and reporting services, it assists asset management companies, private banks, and family offices in meeting their asset management needs.